Biblioteca de litigios de Propecia

La sección A a continuación contiene documentos cuya apertura fue ordenada por la jueza magistrada Peggy Kuo en enero de 2021 en respuesta a la moción de Reuters America LLC de apertura en el litigio de Propecia en EE. UU., Documentos del mismo litigio divulgados voluntariamente al público en octubre de 2020 por los acusados Merck & Co.

La sección B contiene informes de medios publicados que rastrean esta narrativa durante tres décadas a medida que crecía más allá de los Estados Unidos, hacia Canadá, Francia y Alemania.

Tenga en cuenta que la Fundación PFS no participó en ningún litigio mencionado en estos documentos. Más bien, los hemos puesto a disposición como un recurso para las partes interesadas, incluidos los pacientes de PFS y sus seres queridos, proveedores de atención médica, investigadores científicos, funcionarios de agencias reguladoras federales y miembros de los medios de comunicación.

A. Rastro de Papel

Document Date Length
1. Worldwide Marketing Needs Report on Finasteride for Androgenic Alopecia in Men: Merck Human Health Marketing*August 29, 19947 pages
2. Email correspondence between Keith Kaufman and Bruno Gibelin**April 1, 19972 pages
3. Propecia 5-Year End-of-Study Phase III Controlled DataAugust 8, 200030 pages
4. Email correspondence between Prita Pillai and Keith Kaufman regarding presentation of new clinical data on Propecia use** August 16, 20004 pages
5. Email distribution heading for Merck Task Force Meeting held 10/23/2000**
October 20, 20001 page
6. Redlined Propecia product insert*
October 23, 200015 pages
7. Redlined Propecia product insert*
November 3, 200015 pages
8. Supplemental New Drug Application for Propecia: 5-Year Data**April 6, 2001132 pages
9. Email correspondence between Keith Kaufman and Kathleen Peeples-Lamirande regarding a cause for impotence among Propecia patients*January 12, 20062 pages
10. Swedish Medical Products Agency: Preliminary Renewal Assessment Report for Propecia**
November 28, 20062 pages
11. Periodic Safety Report for Finasteride Merck Research Laboratories**
November 30, 20067 pages
12. Email correspondence between Keith Kaufman and Patrick J Ruane**20061 page
13. Merck letter to the Swedish Medical Products Agency regarding reports of persistent ED after quitting Propecia*June 18, 200710 pages
14. Swedish Medical Products Agency: Periodic safety update reports**
November 16, 200712 pages
15. Swedish Medical Products Agency: Preliminary Renewal Assessment Report**April 17, 200822 pages
16. Draft news release: Merck statement Regarding June 2008 Update to the Prescribing Information for Propecia in the European Union*20083 pages
17. Finasteride: Male Pattern Hair Loss Risk Management Plan V 1.0*June 4, 200972 pages
18. Email correspondence between Keith Kaufman and Cynthia Silber**July 20, 20093 pages
19. First Propecia lawsuit filed in the USFebruary 2, 201113 pages
20. FDA Approval Package (NDA 20-788/S-017) for addition of depression to Propecia labelMarch 11, 201156 pages
21. First hearing in Canadian Propecia class action suitNovember 7, 201119 pages
22. Email correspondence between Christine Alberts and Cynthia Silber*April 6, 20112 pages
23. Videotape deposition of Elizabeth Round**December 17, 201552 pages
24. Videotape deposition of Cynthia Silber*April 19, 201625 pages
25. Videotape deposition of Charlotte Merritt**
May 19, 20166 pages
26. Videotape deposition of Paul Howes*June 7, 201641 pages
27. Videotape deposition of Keith Kaufman**

July 12, 2016


13 pages
28. Plaintiff’s Executive Committee Motion for Approval of Settlement PlanApril 10, 201813 pages
29. Order of Motion to Unseal: US Magistrate Judge US District Court, Eastern District of New YorkJanuary 24, 202122 pages
Total documents unsealed24
*Unsealed by court order in January 2021
**Released voluntarily to the public by Merck in October 2020
 Duration
27 years
Total pages602

B. Búsqueda de Medios

The New York Times (US)
December 23, 1997

A Pill for Male Pattern Baldness Wins Approval From the FDA

The Food and Drug Administration announced today that it had given Merck & Company permission to sell a tiny tan octagonal tablet that, experiments show, either promoted the growth of hair or at least stopped hair loss in 83 percent of men.



Critics…complain that no long-term studies have been conducted on the drug.

LawersAndSettlements.com (US)
February 12, 2011

Propecia and Proscar Sexual Dysfunction Class Action Filed

A class lawsuit has been [filed] in the Supreme Court of British Columbia, Canada, by Vancouver resident Michael Miller against Merck Frosst Canada and its affiliated companies…on behalf of Canadian men who used Propecia or Proscar and suffered continuing sexual dysfunction.



Miller, who is in his early 20s, [says] ‘My sexual functioning has not recovered, I have seen specialists and have tried treatments but nothing has worked.’

Hartford Courant (US)
March 3, 2011

Lawsuit Blames Hair Loss Drug For Sexual Dysfunction And Mental Problems

A Connecticut law firm has filed a lawsuit against pharmaceutical manufacturer Merck & Co. on behalf of men who have taken Propecia, a prescription drug that combats hair loss but, its critics say, can also cause severe side effects such as sexual dysfunction and mental impairment.



One Connecticut patient…said that he stopped taking Propecia three years ago after experiencing trouble breathing, sexual dysfunction, anxiety attacks and memory loss. He asked not to be named because his mother still does not know of the severe side effects the drug caused.

LawyerAndSettlements.com (US)
February 24, 2012

Propecia Website Down

Patients looking for information about Propecia may have to search more than anticipated now that the Propecia website has been taken down. The move has sparked speculation about Propecia lawsuits and Propecia side effects.



Although the warning label in the US alerts patients to the possibility of sexual side effects, the label also states that the side effects are temporary… Warning labels in Europe reportedly contain information that the sexual side effects could be permanent.

The Canadian Press (Canada)
April 2, 2013

Class Action Over Baldness, Prostate Drug Side Effects Gets the Go-ahead

Men who suffered ongoing erectile dysfunction after taking prescription drugs to treat prostate problems and male pattern baldness will be able to pursue a class-action lawsuit against the drug maker, a B.C. judge has ruled.



‘The plaintiff asserts that the defendants were aware of the long-term side effects and that the warnings given in Canada were inadequate,’ the judge noted in his ruling.

Toronto Star (Canada)
April 19, 2013

Canadian Men in Class Action Lawsuits Say Drug They Took for Baldness Has Left Them Impotent

More than 500 Canadian men feel they weren’t warned properly about a prescription baldness medication they say has left them impotent, even years after they stopped taking it.



Sean Ramsaran, 26, was prescribed Propecia by his dermatologist in 2009…and now calls himself ‘a useless person…I have nightmares, flashbacks to experiences I had while on the drug.’


'[Merck] acted responsibly and appropriately with respect to Propecia and Proscar throughout the development, marketing and post-marketing monitoring of these medicines,' wrote spokeswoman Lainie Keller in an email. She added there is no scientific data showing the drugs cause persistent impotence after discontinuing use.

Men's Journal (US)
September 2015

Are Hair-Loss Drugs Safe?

Since 2011, 1,245 lawsuits have been filed against Propecia's manufacturer, Merck, alleging that the company failed to warn users of a constellation of sexual and cognitive side effects — which patients and physicians call Post-Finasteride Syndrome... This spring, the National Institutes of Health added PFS to its rare-diseases database. And in March, a California woman filed the first wrongful death suit against Merck.



Merck said the company "stands behind the demonstrated safety and efficacy profile of Propecia." In recent years, it also added depression and persistent sexual problems to its list of possible side effects, deep in the fine print. It intends to defend itself vigorously when the first cases go to court, likely in 2016. The company will undoubtedly argue that millions use Propecia without harm, and that serious problems are rare. Not rare enough, says Steven Rossello, a 32-year-old who filed the first suit against Merck, in 2011.

L’Obs (France)
November 23, 2017 (Part 1)
July 21, 2018 (Part 2)

Prescription Hair-loss Medication Propecia Accused of Ruining Lives

English translation here: Part 1

Finasteride, the Controversial Drug that Medical Authorities Continue to Defend

English translation here: Part 2

In June 2016, 25-year-old Romain took his life. According to his family, his death can be blamed on post-finasteride syndrome. Finasteride is sold by Merck & Co., which may now be subject to civil or criminal prosecution in France.



[F]inasteride trials using a control group were at first limited to a duration of one year, which was then extended for another year–but only for certain patients: those who were healthy. So these trials…all had one failing: they included people in good health and avoided the inclusion of other categories of patients.”

Die Zeit (Germany)
February 22, 2018

A Pill the Doctor Gave Me Destroyed My Life. Patients are now filing lawsuits against the pharmaceutical company

English translation here

The night Thorben Weber lost his manhood ended with, paradoxically, a stunning sunrise in front of his bedroom window. It was July 2015 when he drew his curtains open and looked out at the gently rolling hills of the Black Forest. His body looked the same as always. But nothing worked like it used to. In the ensuing weeks, Weber lost his girlfriend, his apartment and his self-respect.



Neurologists, urologists, dermatologists…they all said Weber was just imagining the discomfort. It took weeks before a professor of andrology at Münster University…made a diagnosis that could explain all the symptoms. ‘You have the Post-Finasteride Syndrome,’ said Michael Zitzmann.

SonntagsZeitung (Switzerland)
December 22, 2018

Finasteride Was Once Considered a Miracle Cure for Hair Loss. Now It’s Going to Court

English translation here

A pill has destroyed Thomas Meier. It’s small, it’s pink and it was supposed to help him with something silly: hair loss…His hair got a little bit thicker, but unpleasant things started happening. ‘I was having erectile problems’ [he] explained. Later on, this was followed by loss of libido, depression and panic attacks.



According to one [study], finasteride users were three times more prone to develop mental health problems than men in the control group… In July 2018 the manufacturers ultimately added to the leaflets that the sexual side effects were nonreversible… And yet the medicine is still on the market.

Le Parisien (France)
March 3, 2019

Propecia: This Mother Accuses the Hair-loss Treatment of Being Responsible for her Son’s Suicide

English translation here

This is the story of Romain Mathieu, a young man who for several years took Propecia, a drug… that can lead to serious side effects ranging from sexual dysfunction to depression… Romain Mathieu ended his life in 2016, but his case will soon be brought to justice, along with two others.



During a final hormonal assessment, his doctor was bewildered: Roman had testosterone levels equivalent to those of an 80-year-old man.

Mediapart (France)
March 13, 2019

The Victims of a Hair-loss Treatment Are Suing MSD

English translation here

For the first time in France, three Propecia victims are suing American pharmaceutical giant Merck Sharp & Dohme. They are…claiming a lack of information about its expected benefits (purely cosmetic), and the risks involved when taking it, which they claim are extremely serious.



‘Before he committed suicide…Romain left a note telling me, If you have the courage, fight,’ says his mother, Sylviane Million-Mathieu.

Deutsche Presse-Agentur (Germany)
May 22, 2019

Hair-loss Trial: Plaintiff Seeks Compensation

English translation here

“I took a hair-loss pill and paid the ultimate price—with my health.” This is how a victim of the hair loss medication describes his situation. Now he is demanding 100,000 euros from the pharmaceutical manufacturer as compensation.



On the first day of the trial…the plaintiff was met with partial success: The defending pharmaceutical companies must hand over detailed information on effects, interactions, side effects, and information about all known suspected cases.

Reuters (US)
September 11, 2019

Court Let Merck Hide Cecrets About a Popular Drug’s Risks

On the morning of March 5, 2013, about 45 minutes before his wife got home, John Pfaff stepped onto the railroad tracks a block away and into the path of a southbound Amtrak train. He was killed on impact. Kelly Pfaff blames Merck for her husband’s death at age 40. In a lawsuit filed in 2015, she alleges that the pharmaceuticals company for years knew but concealed from the public that Propecia could cause the persistent sexual dysfunction and depression that led to her husband’s suicide.



[C]onfidential documents reviewed by Reuters accuse Merck of exaggerating the drug’s safety record… [They] allege that in revisions to the drug’s original 1997 label, Merck understated the number of men who experienced sexual symptoms in clinical trials, and how long those symptoms lasted.

Reuters (US)
January 25, 2021

Judge Orders Merck Documents on Anti-baldness Drug Propecia Unsealed

A US judge granted a Reuters request to unseal Merck & Co. documents produced in lawsuits related to its anti-baldness treatment Propecia, finding that the public’s right to access outweighed the drug maker’s arguments for keeping the information secret.



[P]laintiffs’ lawyers cited internal company communications to allege that in revisions to the drug’s original label, Merck understated the number of men who experienced sexual symptoms in clinical trials and how long those symptoms lasted. Merck settled before responding to the allegations in court. ‘Merck’s arguments for keeping the documents sealed,’ [Judge Peggy] Kuo wrote, ‘are so weak that they would not overcome even a low presumption of access under the common law.’

Reuters (US)
February 13, 2021

Exclusive: Merck Anti-baldness Drug Propecia Has Long Trail of Suicide Reports, Records Show

Newly unsealed court documents and other records show that Merck & Co and US regulators knew about reports of suicidal behavior in men taking the company’s anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label.



Since…2011…the FDA has received more than 700 reports of suicide and suicidal thoughts among people taking Propecia or generic versions… Those included at least 100 deaths. [I]n the first 14 years the drug was on the market, the agency received 34 such reports, including 10 deaths… To this day, the US label contains no mention of suicide or suicidal thoughts.

Daily Mail (UK)
May 21, 2021

Man, 24, Who Said He Was Depressed After Taking Hair Loss Tablet Finasteride Over Five Years Killed Himself by Jumping off Bridge, Inquest Hears

A young man who claimed to be depressed after taking a hair loss tablet for five years killed himself by jumping off a bridge, an inquest heard. Jack Hogg, 24, from Exeter, Devon, was not losing his hair but had been self medicating with finasteride. In the months before his death he became concerned about its side effects including depression.



The inquest heard Jack had researched post-finasteride syndrome online which gave a very bleak outlook and led him to believe he had ruined his life. He died from multiple injuries in the fall from 24 metres from the road bridge.

WDR (Germany)
June 30, 2021

Tricks of the Beauty Industry

Many of those affected have come together in a model class-action lawsuit. This is paid for by a litigation financier from Cologne. There we met attorney Stephan Bensalah.



It's an enormous emotional challenge. You have to imagine: These young men are extremely damaged, some of them are unable to work and their relationships have suffered. Going alone in this situation against a large pharmaceutical company is immensely stressful.